Found Real Customer Outcomes: An Evidence-Based Review of Results

What Found Actually Prescribes

Found clinicians draw from a formulary of FDA-approved weight-management medications, matched to a patient's metabolic profile and insurance coverage. The most commonly reported prescriptions include semaglutide (Wegovy or off-label Ozempic), tirzepatide (Zepbound), metformin, bupropion-naltrexone (Contrave), and topiramate.

The clinical evidence behind these medications varies substantially. Semaglutide 2.4 mg produced 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks in the STEP-1 trial (N=1,961) [1]. Tirzepatide at its highest approved dose (15 mg) delivered 22.5% weight reduction at 72 weeks in SURMOUNT-1 (N=2,539) [2]. These are the ceiling outcomes. Patients prescribed metformin or Contrave through Found will see more modest results: the COR-I trial showed bupropion-naltrexone produced approximately 6.1% weight loss at 56 weeks [3].

Not every Found member receives a GLP-1. Insurance formularies, prior authorization requirements, and clinical contraindications mean many patients start on older, less expensive agents. This distinction matters when interpreting customer testimonials.

Parsing Customer-Reported Outcomes

Online reviews of Found cluster into two distinct populations: those who obtained GLP-1 prescriptions and those prescribed non-GLP-1 alternatives. The GLP-1 group reports outcomes broadly consistent with published trial data. The non-GLP-1 group shows higher variability and more mixed satisfaction.

A 2024 retrospective of real-world semaglutide use published in JAMA Network Open found that patients in clinical practice lost a mean of 5.9% body weight at 3 months and 10.9% at 12 months [4]. These figures run below the controlled trial environment, which is expected. Trial participants receive structured dietary counseling, regular weigh-ins, and dose-escalation protocols that real-world settings may not replicate with the same rigor.

Found's own published case studies should be interpreted with survivorship bias in mind. Patients who discontinue early (due to side effects, cost, or inadequate response) do not typically contribute testimonials. The STEP-1 extension data demonstrated that approximately two-thirds of weight lost on semaglutide returned within one year of discontinuation [5], which highlights the importance of sustained treatment access.

Is Found Legitimate as a Clinical Program?

Found operates as a legitimate telehealth medical practice with licensed prescribers in each state. The program requires an intake questionnaire, medical history review, and (in most cases) lab work before prescribing. This aligns with the Endocrine Society's 2024 guidelines on pharmacological obesity management, which recommend comprehensive metabolic assessment before initiating anti-obesity medications [6].

The platform diverges from some competitors by excluding compounded semaglutide and tirzepatide from its formulary. This is a meaningful clinical distinction. The FDA issued warnings about compounded GLP-1 products, noting reports of adverse events associated with salt forms (semaglutide sodium) not bioequivalent to the approved product [7]. Found's restriction to FDA-approved branded medications reduces risk but increases cost.

Dr. Rekha Kumar, an endocrinologist and former Chief Medical Officer at Found, has stated: "Weight regain after stopping medication is not a failure of willpower. It reflects the biological reality that obesity is a chronic disease requiring ongoing treatment." This framing aligns with the American Association of Clinical Endocrinology's consensus statement positioning obesity as a chronic, relapsing condition [8].

Found vs. Alternatives: Cost and Access Comparison

Found's membership fee ($99-$199/month depending on plan tier) covers clinician access, messaging, and the behavioral coaching platform. Medication cost is separate. For patients with insurance coverage for GLP-1s, total out-of-pocket may be comparable to a traditional endocrinology visit with copay. Without insurance, branded semaglutide runs approximately $1,300-$1,400/month at retail.

Competitors like Calibrate ($159/month for 12 months), Ro Body ($145/month including compounded medication), and Sequence ($99/month membership) occupy similar price points but differ in formulary approach. Ro Body and Hims/Hers include compounded GLP-1s in their membership pricing, offering lower total cost but with the regulatory and bioequivalence caveats noted above.

A direct cost-effectiveness comparison depends entirely on which medication a patient receives. The Institute for Clinical and Economic Review (ICER) 2022 report estimated semaglutide's cost-effectiveness threshold at approximately $7,500-$9,800 per quality-adjusted life year when accounting for cardiovascular risk reduction [9]. For patients who can access branded GLP-1s through Found's insurance partnerships, the value proposition strengthens considerably.

Found's BCBS partnership deserves specific mention. Select Blue Cross Blue Shield plans cover both the membership fee and medication cost as a covered benefit, reducing member out-of-pocket to standard specialist copays. This employer-channel strategy differentiates Found from direct-to-consumer competitors that operate entirely outside insurance frameworks.

The GLP-1 Efficacy Question in Telehealth Settings

Does receiving a GLP-1 through a telehealth platform like Found produce different outcomes than receiving it through a brick-and-mortar obesity medicine clinic? The evidence suggests the delivery model matters less than medication adherence and dose optimization.

The STEP-5 trial demonstrated that semaglutide maintained 15.2% weight loss at 104 weeks in patients who continued treatment [10]. The primary predictor of success was not visit frequency or in-person contact but sustained medication use at target dose. Telehealth models that maintain prescribing continuity and monitor for dose-limiting side effects can theoretically match in-person outcomes.

A 2023 analysis in Obesity examined telehealth-delivered anti-obesity medication programs and found no statistically significant difference in 6-month weight loss between virtual and in-person delivery (mean difference 0.4%, 95% CI crossing null) [11]. The key variables were time-to-therapeutic-dose and medication persistence, not visit modality.

Where telehealth programs like Found may underperform is in managing complex patients with multiple comorbidities, those requiring frequent lab monitoring (e.g., tirzepatide with a history of pancreatitis), or patients who need procedural interventions like intragastric balloons when pharmacotherapy fails.

Retention, Discontinuation, and Weight Regain

The most significant limitation of any subscription telehealth weight-loss program is the discontinuation problem. When patients leave the platform (due to cost, insurance changes, or perceived goal completion), medication access typically ends.

The SELECT cardiovascular outcomes trial (N=17,604) established that semaglutide reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity [12]. This benefit requires ongoing treatment. The Endocrine Society guideline explicitly states: "Anti-obesity medications should be continued long-term if clinically effective and well tolerated" [6].

Found addresses retention through its coaching layer, monthly check-ins, and medication management continuity. Whether this produces superior long-term adherence compared to standard care remains unquantified in peer-reviewed literature specific to Found. The program has not published its own retention or outcomes data in indexed journals, which limits independent verification of claimed success rates.

What the Behavioral Component Adds

Found pairs prescriptions with app-based behavioral interventions: food logging, movement tracking, sleep optimization, and cognitive-behavioral strategies for eating behaviors. The evidence for combined pharmacotherapy plus behavioral intervention is stronger than either alone.

The SCALE Maintenance trial showed that adding liraglutide to behavioral intervention after initial lifestyle-induced weight loss produced an additional 6.2% loss versus placebo plus behavioral intervention [13]. The Look AHEAD trial demonstrated that intensive lifestyle intervention alone produced only 2.5% sustained weight loss at 9.6 years, a ceiling that pharmacotherapy meaningfully raises [14].

The American Heart Association's 2023 scientific statement on obesity pharmacotherapy recommends combining medications with "comprehensive lifestyle intervention including dietary modification, physical activity, and behavioral strategies" [15]. Found's dual approach aligns with this guidance, though the intensity and individualization of its behavioral component has not been independently benchmarked against structured programs like the Diabetes Prevention Program.

Side Effects Reported by Found Users

Customer reviews consistently mention the expected GLP-1 side-effect profile: nausea (reported in 44% of semaglutide-treated patients in STEP-1 [1]), constipation, injection-site reactions, and early satiety. These match the published safety data and typically attenuate with dose stabilization.

Less commonly discussed but clinically relevant: the STEP-1 trial reported a 7.0% discontinuation rate due to gastrointestinal adverse events in the semaglutide arm versus 3.1% with placebo [1]. Found's asynchronous messaging model may present challenges for patients experiencing acute side effects who need same-day clinical guidance on dose modification or anti-emetic strategies.

The FDA's post-marketing safety data for semaglutide includes rare signals for pancreatitis, gallbladder events, and suicidal ideation that require ongoing monitoring [7]. Any telehealth program prescribing these agents must maintain protocols for screening and escalation. Found's intake process includes mental health screening questions, which partially addresses the psychiatric monitoring concern.

Who Benefits Most from Found

The optimal Found candidate has a BMI of 30+ (or 27+ with at least one weight-related comorbidity), insurance that covers GLP-1 medications, and a preference for virtual care over in-person visits. Patients meeting these criteria can access medications with strong evidence bases at relatively low out-of-pocket cost through the platform's insurance integrations.

Patients without GLP-1 coverage face a different value calculus. Paying $99-$199/month for access to metformin or Contrave (both available as inexpensive generics through any primary care physician) represents a premium over standard care that the behavioral coaching component must justify independently. Whether Found's app-based coaching delivers sufficient incremental value over free resources (the CDC's Diabetes Prevention Program, for instance, costs patients nothing) is a question each prospective member should evaluate against their specific needs and budget.

The 2022 U.S. Preventive Services Task Force recommendation for intensive behavioral interventions in adults with BMI ≥ 30 specifies a minimum of 12-26 contact hours over 12 months [16]. Found's coaching model has not publicly disclosed whether it meets this contact-hour threshold.